EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antivirals Targeting Coronavirus RNA ‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID ‐19 Clinical Trials

Harald Brüssow iD

Microbial Biotechnology · 2026

DOI: 10.1111/1751-7915.70342 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, 2026. Verfasst von Harald Brüssow. Beteiligte Einrichtung: Department of Biosystems, Laboratory of Gene Technology, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Coronavirus RNA-Dependent RNA Polymerase, Viral Nonstructural Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid global spread of SARS‐CoV‐2 triggered an unprecedented effort to develop effective antivirals. Among the first approved agents was remdesivir, an injectable nucleoside analogue developed by Gilead Sciences, that led to chain termination of viral RNA synthesis and showed broad antiviral activity against RNA viruses. Early clinical results were mixed: The US ACTT‐1 trial reported an accelerated recovery and reduced mortality in treated patients, while the WHO Solidarity and a European trial revealed no impact of remdesivir on mortality. In contrast, a US trial in outpatients demonstrated a clear clinical benefit when treatment was administered early. Molnupiravir, an orally applicable nucleoside analogue developed by Merck, induces lethal mutations in the viral genome rather than chain termination. Molnupiravir showed in vivo antiviral activity against coronaviruses in different animals. In MOVe‐OUT trials, molnupiravir reduced the rate of hospitalisation in treated outpatients. In the PANORAMIC trial, molnupiravir reduced the time to recovery in outpatients but not their rate of hospitalisation. No drug effect of molnupiravir was seen in the RECOVERY trial with hospitalised COVID‐19 patients. Using structural biology and medicinal chemistry approaches, Pfizer developed nirmatrelvir, an oral inhibitor of the major coronavirus protease. In high‐risk but not in standard‐risk COVID‐19 patients, the combination nirmatrelvir/ritonavir reduced the rate of hospitalisation (EPIC HR and SR trials). Retrospective cohort studies showed treatment effects in defined patient groups. This review compares the efficacy and clinical performance of different antivirals, including emerging drugs such as obeldesivir and alternative protease inhibitors (lopinavir, simnotrelvir). It further examines their roles in prophylaxis, treatment of long covid symptoms, pharmacological considerations and antiviral resistance. Particular attention is given to factors underlying variable outcome of the trials, including viral variant evolution, population immunity increases, disease severity changes and timing of therapy initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2Coronavirus RNA-Dependent RNA PolymeraseViral Nonstructural ProteinsHumansClinical Trials as TopicCOVID-19AnimalsCOVID-19 Drug TreatmentCoronavirus 3C ProteasesProlineTreatment OutcomeCytidineHydroxylamines

Substanzen

Antiviral AgentsmolnupiravirCoronavirus RNA-Dependent RNA PolymeraseCoronavirus 3C ProteasesViral Nonstructural ProteinsProlineCytidineHydroxylamines

Autor:innen und Institutionen

  • Department of Biosystems, Laboratory of Gene Technology, KU Leuven, Leuven, Belgium.

ORCID-Profile: Harald Brüssow

Zitieren

APA

Brüssow, H. (2026). Antivirals Targeting Coronavirus RNA ‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID ‐19 Clinical Trials. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70342

Vancouver

Brüssow H. Antivirals Targeting Coronavirus RNA ‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID ‐19 Clinical Trials. Microbial Biotechnology. 2026. doi:10.1111/1751-7915.70342

BibTeX
@article{Brssow2026,
  author = {Brüssow, Harald},
  title = {Antivirals Targeting Coronavirus RNA ‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID ‐19 Clinical Trials},
  journal = {Microbial Biotechnology},
  year = {2026},
  doi = {10.1111/1751-7915.70342}
}
Kostenlos starten →